Incidence of Choroidal Neovascularization in the Fellow Eye in the Comparison of Age-related Macular Degeneration Treatments Trials
Open accessAbstract
Objective To assess the influence of drug; dosing regimen; and traditional, nontraditional, and genetic risk factors on the incidence of choroidal neovascularization (CNV) in the fellow eye of patients treated for CNV with ranibizumab or bevacizumab.Design Cohort study of patients enrolled in a multicenter, randomized clinical trial.Participants Patients with no CNV in the fellow eye at the time of enrollment in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).Methods Eligibility criteria for the clinical trial required that study eyes have evidence on fluorescein angiography and optical coherence tomography of CNV secondary to age-related macular degeneration (AMD) and visual acuity between 20/25 and 20/320. Treatment for the study eye was assigned randomly to either ranibizumab or bevacizumab and to 3 different regimens for dosing over a 2-year period. The genotypes for 4 single nucleotide polymorphisms (SNPs) associated with risk of AMD were determined. Only patients without CNV in the fellow eye at baseline were considered at risk. The CATT ophthalmologists examined patients every 4 weeks through 2 years and recorded treatment for CNV in the fellow eye.Main outcome measures Development of CNV in the fellow eye.Results Among 1185 CATT participants, 727 (61%) had no CNV in the fellow eye at enrollment. At 2 years, CNV had developed in 75 (20.6%) of 365 patients treated with ranibizumab and in 60 (16.6%) of 362 patients treated with bevacizumab (absolute difference, 4.0%; 95% confidence interval [CI], -1.7% to 9.6%; P = 0.17). The risk ratio for pro re nata dosing relative to monthly dosing was 1.1 (95% CI, 0.8-1.6). Greater elevation of the retinal pigment epithelium and fluid in the foveal center of the study eye were associated with increased incidence of CNV in the fellow eye. Incidence was not associated with genotype on rs1061170 (CFH), rs10490924 (ARMS2), rs11200638 (HTRA1), and rs2230199 (C3; P>0.35).Conclusions Through 2 years, there was no statistically significant difference between ranibizumab and bevacizumab in incidence of CNV in the fellow eye. Genotype on 4 SNPs previously found to be associated with AMD did not affect the risk of CNV in the fellow eye among CATT patients.Financial disclosure(s) Proprietary or commercial disclosure may be found after the references.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The annual incidence of nAMD occurrence in the second eye is 4%-19%.
“The annual incidence of nAMD occurrence in the second eye falls within the range of 4%–19%.19”
From Nonclinical study of ixo-vec gene therapy for nAMD supports efficacy for a human dose of 6E10 vg/eye and staggered dosing of fellow eyes (2025) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Cillà, S. D., Farruggio, S., Vujosevic, S., Raina, G., Filippini, D. A., Gatti, V., Clemente, N., Mary, D., Vezzola, D., Casini, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479441 · Cited by 5,154 · see citing works
(2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.10.1417 · Cited by 3,285 · see citing works
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669 · see citing works
Age-related macular degeneration
Lim, L. S., Mitchell, P., Seddon, J. M., Holz, F. G., & Wong, T. Y. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60282-7 · Cited by 1,764 · see citing works
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715 · see citing works
Self-citationA Simplified Severity Scale for Age-Related Macular Degeneration: AREDS Report No. 18
(2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.11.1570 · Cited by 807 · see citing works
Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy
Avery, R. L., Pearlman, J. A., Pieramici, D. J., Rabena, M., CASTELLARIN, A. A., Nasir, M. A., Giust, M. J., Wendel, R., & Patel, A. C. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.05.064 · Cited by 802 · see citing works
Self-citationRanibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Wordsworth, S., & Reeves, B. C. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.04.015 · Cited by 779 · see citing works
(2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.11.1484 · Cited by 739 · see citing works
Pharmacokinetics of Intravitreal Bevacizumab (Avastin)
Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., & Singh, R. J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.01.017 · Cited by 683 · see citing works
Self-citationPharmacokinetics of Intravitreal Ranibizumab (Lucentis)
Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., Ezzat, M. K., & Singh, R. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.09.012 · Cited by 543 · see citing works
Self-citationPreclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal Administration
Gaudreault, J., Fei, D., Rusit, J., Suboc, P., & Shiu, V. (2005) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.04-0601 · Cited by 501 · see citing works
Sato, T., Wada, K., Arahori, H., et al. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.07.005 · Cited by 328 · see citing works
Ten-Year Incidence and Progression of Age-Related Maculopathy
Wang, J. J., Rochtchina, E., Lee, A. J., Chia, E., Smith, W. T., Cumming, R. G., & Mitchell, P. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.07.017 · Cited by 320 · see citing works
Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease
Tolentino, M. J. (2011) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2010.08.006 · Cited by 300 · see citing works
Nomoto, H., Shiraga, F., Kuno, N., Kimura, E., Fujii, S., Shinomiya, K., Nugent, A. K., Hirooka, K., & Baba, T. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-3148 · Cited by 269 · see citing works
Curtis, L. H. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.223 · Cited by 192 · see citing works
Gaudreault, J., Fei, D., Beyer, J. C., Ryan, A. M., Rangell, L. K., Shiu, V., & Damico, L. A. (2007) · Retina · doi:10.1097/iae.0b013e318134eecd · Cited by 182 · see citing works
Carneiro, Â. M., Costa, R., Falcão, M. S., Barthelmes, D., Mendonça, L. S., Fonseca, S. L., Gonçalves, R., Gonçalves, C., Falcão‐Reis, F., & Soares, R. A. (2011) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2011.02240.x · Cited by 147 · see citing works
Hagstrom, S. A., Ying, G.-S., Pauer, G. J. T., Sturgill-Short, G. M., Huang, J., Callanan, D. G., Kim, I. K., Klein, M. L., Maguire, M. G., & Martin, D. F. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.11.037 · Cited by 142 · see citing works
Self-citationPreclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab
Meyer, C. H., & Holz, F. G. (2011) · Eye · doi:10.1038/eye.2011.66 · Cited by 138 · see citing works
Matsuyama, K., Ogata, N., Matsuoka, M., Wada, M., Takahashi, K. A., & Nishimura, T. (2010) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.156810 · Cited by 136 · see citing works
Brechner, R. J., Rosenfeld, P. J., Babish, J. D., & Caplan, S. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2010.11.017 · Cited by 131 · see citing works
Genetics of age-related macular degeneration: current concepts, future directions
DeAngelis, M. M., Silveira, A. C., Carr, E. A., & Kim, I. K. (2011) · Seminars in Ophthalmology · doi:10.3109/08820538.2011.577129 · Cited by 94 · see citing works
Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits
Sinapis, Sinapis, C., Σινάπης, Δ., Routsias, J. G., Pantopoulou, A., Baltatzis, S., Patsouris, E., & Perrea, D. N. (2011) · Clinical ophthalmology · doi:10.2147/opth.s19555 · Cited by 87 · see citing works
BARBAZETTO, I. A., Saroj, N., Shapiro, H., Wong, P., Ho, A. C., & Freund, K. B. (2010) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2010.01.007 · Cited by 85 · see citing works
The Effect of Methotrexate on Corneal Neovascularization in Rabbits
Byun, Y., & Chung, S. K. (2010) · Cornea · doi:10.1097/iae.0b013e3181e46ad8 · Cited by 73 · see citing works
DeCroos, F. C., Toth, C. A., Stinnett, S. S., Heydary, C. S., Burns, R., & Jaffe, G. J. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.06.040 · Cited by 67 · see citing works
Pieramici, D. J., & Bressler, S. B. (1998) · Current Opinion in Ophthalmology · doi:10.1097/00055735-199806000-00007 · Cited by 55 · see citing works
Al-Dhibi, H. A., & Khan, A. O. (2009) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2009.03.006 · Cited by 54 · see citing works
Grunwald, J. E., Daniel, E., Ying, G., Pistilli, M., Maguire, M. G., Alexander, J., Martin, R., Parker, C., Sepielli, K., Blodi, B. A., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.013 · Cited by 53 · see citing works
Self-citationBevacizumab (Avastin) for retinopathy of prematurity: Wrong dose, wrong drug, or both?
Avery, R. L. (2012) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2011.11.002 · Cited by 48 · see citing works
Self-citationSubmacular Surgery Trials Research Group* (2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.10.1323 · Cited by 48 · see citing works
BILATERAL EFFECT OF UNILATERAL RANIBIZUMAB IN PATIENTS WITH UVEITIS-RELATED MACULAR EDEMA
Acharya, N. R., Sittivarakul, W., Ying, Q., Hong, K. C., & Lee, S. M. (2011) · Retina · doi:10.1097/iae.0b013e318213da43 · Cited by 40 · see citing works
RISK FACTORS FOR CHOROIDAL NEOVASCULARIZATION AND VISION LOSS IN THE FELLOW EYE STUDY OF CNVPT
Prenner, J. L., ROSENBLATT, B. J., Tolentino, M. J., Ying, G., Javornik, N. B., Maguire, M. G., & Ho, A. C. (2003) · Retina · doi:10.1097/00006982-200306000-00004 · Cited by 39 · see citing works
Self-citationDavidović, S., Nikolić, S., Ćurić, N., Latinović, S., Drašković, D., Čabarkapa, V., & Stosić, Z. (2012) · European Journal of Ophthalmology · doi:10.5301/ejo.5000118 · Cited by 35 · see citing works
Lechanteur, Y. T. E., van de Ven, J. P. H., Smailhodzic, D., Boon, C. J. F., Klevering, B. J., Fauser, S., Groenewoud, J. M. M., van der Wilt, G. J., den Hollander, A. I., & Hoyng, C. B. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7731 · Cited by 28 · see citing works
Tamura, H., Tsujikawa, A., Yamashiro, K., Akagi-Kurashige, Y., Nakata, I., Nakanishi, H., Hayashi, H., Ooto, S., Otani, A., & Yoshimura, N. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.03.042 · Cited by 27 · see citing works
Tuebingen Bevacizumab Study Group, Ziemssen, F., Zhu, Q., Peters, S., Grisanti, S., Wardani, M. E., Szurman, P., Bartz‐Schmidt, K. U., & Ziemssen, T. (2008) · International Ophthalmology · doi:10.1007/s10792-008-9221-7 · Cited by 24 · see citing works
DeCroos, F. C., Toth, C. A., Stinnett, S. S., Heydary, C. S., Russell, S. R., & Jaffe, G. J. (2012) · Investigative Ophthalmology & Visual Science · Cited by 8 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [31]Lucentis (ranibizumab injection) [package insert] San Francisco, CA Genentech Inc 2013 Available at: http://www.gene.com/gene/products/information/pdf/lucentis-prescribing.pdf Accessed March 6, 2013 AQ: note URL displays updated package insert, review to confirm information being cited is still present
Cited by
Sorted by citations
Predicting conversion to wet age-related macular degeneration using deep learning
Yim, J., Chopra, R., Spitz, T., Winkens, J., Obika, A., Kelly, C., Askham, H., Lukic, M., Huemer, J., Fasler, K., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0867-7 · Cited by 297 · see citing works
Patel, S. S., Lally, D. R., Hsu, J., Wykoff, C. C., Eichenbaum, D., Heier, J. S., Jaffe, G. J., Westby, K., Desai, D., Zhu, L., et al. (2023) · Eye · doi:10.1038/s41433-023-02497-w · Cited by 147 · see citing works
Current best clinical practices—management of neovascular AMD
Brown, D., Heier, J. S., Boyer, D. S., Freund, K. B., Kaiser, P., Kim, J. E., & Sarraf, D. (2017) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126417725946 · Cited by 23 · see citing works
Poulsen, K., Hanna, K., Nieves, J., Nguyen, N., Sharma, P., Grishanin, R., Corbau, R., & Kiss, S. (2025) · Molecular Therapy Methods & Clinical Development · doi:10.1016/j.omtm.2025.101430 · Cited by 8 · see citing works
“19 Consequently, a considerable interval ranging from months to years may transpire between the initial treatment of the fi rst eye and the subsequent necessity for treatment in the second eye.”
- Authors
- Maguire, M. G., Daniel, E., Shah, A. R., Grunwald, J. E., Hagstrom, S. A., Avery, R. L., Huang, J., Martin, R. W., Roth, D. B., Castellarin, A. A., Bakri, S. J., Fine, S. L., & Martin, D. F.
- Affiliations
- University of Pennsylvania (US)
- Cleveland Clinic (US)
- California Retina Consultants (US)
- Mayo Clinic (US)
- University of Colorado Anschutz (US)
- ORCID
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 120
- Issue
- 10
- Pages
- 2035-2041
- ISSN
- 0161-6420 (ISSN-L)
- PMC
- PMC3758381
- OpenAlex
- W2102366909
- Cited by
- 93
- References
- 41
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 6 · 2023: 5 · 2022: 3 · 2021: 9 · 2020: 9 · 2019: 11 · 2018: 9 · 2017: 10 · 2016: 12 · 2015: 6 · 2014: 2 · 2013: 3
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Eye Institute (U10EY017825, U10EY017826, U10EY017823, U10EY017828)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- choroidal neovascularization, fellow eye, age-related macular degeneration, ranibizumab, bevacizumab, anti-VEGF therapy, pro re nata dosing, dosing regimen, single nucleotide polymorphisms, complement factor H, ARMS2, genetic risk factors, retinal pigment epithelium elevation, CATT
- MeSH terms
- Bevacizumab, Ranibizumab, High-Temperature Requirement A Serine Peptidase 1, Aged, Aged, 80 and over, Complement C3, Dose-Response Relationship, Drug, Female, Genotype, Humans, Macular Degeneration, Male, Middle Aged, Proteins, Serine Endopeptidases, Cohort Studies, Incidence, Complement Factor H, Genetic Predisposition to Disease, Choroidal Neovascularization, Angiogenesis Inhibitors, Polymorphism, Single Nucleotide, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
